A recent article in the Pink Sheet explores the implications of actions from US lawmakers regarding legislation restricting clinical trials in China. While the immediate impact might be minimal, Anshul Mangal, President, Project Farma – a Precision for Medicine company, weighs in on how a broader focus could significantly alter the landscape of multinational drug development.
In the Pink Sheet’s “Clinical Trials in China: As US Lawmakers Consider Crackdown, Here Are The Implications”, Anshul:
- Emphasizes the strategic shifts already underway in the industry, pointing to companies that are proactively adjusting to potential changes by seeking alternative trial locations in the US, Europe, and other regions in Asia.
- Warns that expanding the legislative focus beyond Chinese military hospitals could have "massive" consequences, potentially leading to a divided global research ecosystem.
- Highlights a silver lining of opportunity for growth within the US, underscoring the importance of bolstering domestic capabilities to mitigate supply chain risks—particularly those highlighted by the COVID-19 pandemic.
- Advises biotech leaders to take close examination of their reliance on China, urging companies to prepare for potential changes in the regulatory environment.
Read more about the potential impact of US-China clinical trial regulations in “Clinical Trials in China: As US Lawmakers Consider Crackdown, Here Are The Implications”, published in the Pink Sheet. Subscription required.